- Today, we take an in-depth look at Reata Pharmaceuticals.
- After surging north of $250 in early February 2020, the shares have lost ~55% of their value.
- An August 2020 regulatory update added timing uncertainty to one of its Nrf2 targeting candidates (Bard) and FDA approval uncertainty to a second (Omav).
- Pursuing multiple indications with no FDA-approved therapies and strongly statistically significant results, Reata warranted a deeper dive.
- A full investment analysis is provided in the paragraphs below.
For further details see:
Reata Pharmaceuticals Can Rally